Published in Curr Treat Options Oncol on December 01, 2014
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | NCT01004224
Vandetanib in Advanced NSCLC With RET Rearrangement | NCT01823068
Ponatinib in Advanced NSCLC w/ RET Translocations | NCT01813734
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | NCT01804530
Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948
BGJ398 for Patients With Tumors With FGFR Genetic Alterations (CBGJ398XUS04) | NCT02160041
EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS) | NCT02183870
Sunitinib in Never-Smokers With Lung Adenocarcinoma | NCT01829217
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | NCT01526473
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | NCT01324479
Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | NCT01976741
A Study of AMG 337 in Subjects With Advanced Solid Tumors | NCT01253707
Safety Study of MGAH22 in HER2-positive Carcinomas | NCT01148849
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1) | NCT02183883
Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer | NCT01531361
AUY922 in Patient With Stage IV NSCLC (NSCLC) | NCT01922583
Study of ABT-700 in Subjects With Advanced Solid Tumors | NCT01472016
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | NCT02132598
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | NCT02055066
Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors (HMPL) | NCT02133157
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes. Genes Chromosomes Cancer (2015) 0.85
(-)-Guaiol regulates RAD51 stability via autophagy to induce cell apoptosis in non-small cell lung cancer. Oncotarget (2016) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One (2011) 3.10
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 2.65
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res (1988) 2.36
Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A (1987) 2.11
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol (2014) 2.10
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res (2012) 2.04
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol (2013) 2.04
Characterization of an activated human ros gene. Mol Cell Biol (1986) 1.97
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell (2011) 1.92
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res (2013) 1.68
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer (2012) 1.66
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer (2014) 1.65
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol (2003) 1.55
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol (2012) 1.46
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res (2014) 1.46
FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol (2012) 1.43
A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol (2013) 1.37
FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res (2014) 1.36
De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther (2009) 1.33
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol (2013) 1.31
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One (2013) 1.17
Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol (2012) 1.17
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene (2005) 1.16
Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer (1996) 1.13
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res (2014) 1.11
A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res (2004) 1.07
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer (2004) 0.99
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol (2013) 0.98
BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One (2014) 0.96
Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients. Tumour Biol (2014) 0.92
RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia (2012) 0.90
Mouse model for ROS1-rearranged lung cancer. PLoS One (2013) 0.88
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis (2014) 0.82
The democratization of the oncogene. Cancer Discov (2014) 0.81
KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. Mol Cancer (2014) 0.80
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol (2011) 2.88
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer (2012) 1.70
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One (2010) 1.69
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J Biol Chem (2007) 1.44
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity (2003) 1.43
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res (2013) 1.38
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer (2012) 1.31
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.99
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer (2013) 0.95
Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer (2013) 0.92
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol (2012) 0.92
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book (2013) 0.87
A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS One (2012) 0.81
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol (2013) 0.79
Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol (2010) 0.78
Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol (2011) 0.78
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer (2013) 0.78
Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs (2013) 0.78
Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer? Nat Rev Clin Oncol (2013) 0.76
A time to test, a time to treat. J Thorac Dis (2012) 0.75
Rearranging Detection of Gene Rearrangements. J Thorac Oncol (2015) 0.75
Oncogenic fusions involving exon 19 of ALK. J Thorac Oncol (2012) 0.75
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Arch Pathol Lab Med (2016) 0.75